ASP Isotopes Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Elliot Mann
- Full Time Employees
- 136
- Sector
- Basic Materials
- Industry
- Chemicals
- Address
- 433 Plaza Real Washington FL United States of America 33432
- IPO Date
- Nov 10, 2022
- CIK
- 0001921865
- Website
- aspisotopes.com
- Similar Companies
- Business
- ASP Isotopes Inc. (ASPI) operates as a development-stage advanced materials company focused on developing proprietary technologies and processes to produce and enrich isotopes for nuclear medicine, green energy generation, semiconductors, quantum computing, and related industries; core offerings encompass the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies for separating isotopes such as Carbon-14 (C-14), Molybdenum-100 (Mo-100), Molybdenum-98 (Mo-98), Silicon-28 (Si-28), and Ytterbium-176 (Yb-176) used in pharmaceuticals, agrochemicals, nuclear medical imaging, and high-assay low-enriched uranium (HALEU), Lithium-6, and Chlorine-37 for advanced nuclear fuels; the company also provides nuclear medicine services through its 51% majority stake in PET Labs (Pty) Ltd., a leader in South Africa and sub-Saharan Africa. Incorporated in Delaware in September 2021 with principal executive offices in Washington, DC, ASP Isotopes maintains enrichment facilities in South Africa and conducts research and development across two main segments: Nuclear Fuels and Specialist Isotopes and Related Services, targeting healthcare, technology, and energy markets primarily in the United States, South Africa, and the United Kingdom. Recent developments include the early commissioning of a Quantum Enrichment facility for Ytterbium-176 and commencement of commercial production for enriched Carbon-14 and Silicon-28 in 2025; expansion through three new facilities and strategic partnerships, such as a Series Seed funding investment of $5 million in IsoBio, Inc. in July 2025 to advance antibody-isotope conjugates for cancer treatment with potential manufacturing via PET Labs; an announced agreement for the potential acquisition of Renergen Limited to create a global critical materials leader; acquisition of intellectual property assets and a 30 SWU facility by subsidiary Quantum Leap Energy LLC in October 2025; and a return of Executive Chairman and CEO Paul Mann from temporary leave in December 2025.
ASP Isotopes Stock Surges After Silicon-28 Facility Restart
ASP Isotopes Implements Engineering Enhancements to Silicon-28 Enrichment Facility; Successfully Restarts First 18 Stages of Silicon-28 Enrichment Facility; Commercial Shipments of Enriched Silicon-28 Expected to Commence in Q3 2026
ASP Isotopes Announces HALEU Supply MOU Through Subsidiary, Shares Move Higher
Quantum Leap Energy Enters into Memorandum of Understanding with European Nuclear Technology Company for Advanced Nuclear Fuel Supply Collaboration
Quantum Leap Energy Appoints Dr. Peter Fiske to Strategic Advisory Board
Insider Selling: ASP Isotopes (NASDAQ:ASPI) Director Sells $60,654.82 in Stock
ASP Isotopes (NASDAQ:ASPI) COO Sells $117,225.00 in Stock
ASP Isotopes (NASDAQ:ASPI) CFO Sells $126,719.52 in Stock
ASP Isotopes Inc. Provides Business Update
ASP Isotopes to Host Business Update Conference Call on April 13, 2026, at 8:00 AM ET
Did ASP Isotopes Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Grabar Law Office Investigates Claims on Behalf of Investors of ASP Isotopes Inc. (ASPI) as Class Action Survives Motion to Dismiss
ASP Isotopes Announces Strategic Collaboration Between Quantum Leap Energy and University of Bristol to Design Advanced Laser Research Facility
Why ASP Isotopes Stock Is Surging Today
ASP Isotopes Completes Well Drilling Required for Phase 1 of Renergen Helium Project Four Months Ahead of Schedule
Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf
OpenAI in talks with private equity firms on potential $10B enterprise AI venture: reports
Helium supply shock highlights fragile global market, D3 Energy CEO says
Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); EOS Energy Enterprise, Inc. (NASDAQ: EOSE); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf
Did ASP Isotopes Inc. Insiders Breach their Fiduciary Duties to Shareholders?